## **ICMJE DISCLOSURE FORM**

υa	te: <u>2022-</u>	10-27	
		工基	· 1000 1000 1000 1000 1000 1000 1000 10
		IN WANG	
Ma	nuscript Title: <u>Intrahepatic</u>	portal vein variant: A si	ngle dilated intrahepatic portal vein coursing to the umbilical
fiss	sure without second-order b	<u>ranches</u>	
Ma	nuscript number (if known)	): HBSN-22-5	516
rel par to rel The ma to me	ated to the content of your ries whose interests may be transparency and does not ationship/activity/interest, ationship/activity/interest, at following questions apply muscript only.  The author's relationships/activity and the epidemiology of hypertodication, even if that medicatem #1 below, report all su	manuscript. "Related" re affected by the conternecessarily indicate a bid it is preferable that you to the author's relation ivities/interests should ension, you should declaration is not mentioned pport for the work repo	ships/activities/interests as they relate to the <u>current</u> be <u>defined broadly</u> . For example, if your manuscript pertains are all relationships with manufacturers of antihypertensive
Cite	time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the ini	itial planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: p	ast 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
2	Royalties or licenses	None	
	Noyalties of ficerises	HOTIC	

Consulting fees

None

4

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Please summarize the above conflict of interest in the following box:

No conflict of interest to declare.	

Please place an "X" next to the following statement to indicate your agreement:

\_\_ X \_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## **ICMJE DISCLOSURE FORM**

Date:	2022-10-27				
		A last			
Your Name:	Shunda Du				
Manuscript Title: Intr	ahepatic portal vein va	ariant: A single dilated intrahepatic portal vein coursing to the umbilical			
fissure without second					
Manuscript number (i		HBSN-22-516			
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> .  The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.					

		Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)
		none (add rows as needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	26 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	30 Hioritas
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
	testimony	
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	None
12	Receipt of equipment,	None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	None
13	financial interests	Hone

Please summarize the above conflict of interest in the following box:

No conflict of interest to declare.		

Please place an "X" next to the following statement to indicate your agreement:

X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.	